A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
Bambusa Therapeutics · NCT06808477
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–72 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Phase 1
- Target enrollment
- 237
- US sites recruiting
- 3
- Study start
- February 27, 2025
- Record last updated
- September 29, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).
Being studied: BBT001; Placebo
Conditions: Atopic Dermatitis
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Key Inclusion Criteria
- Negative pregnancy tests for women of childbearing potential.
- Willingness to refrain from alcohol consumption for 24 hours prior to each study visit.
- Non-smokers, healthy current smokers (≤5 cigarettes/day), or ex-smokers.
- Adequate contraception use (for men and women of childbearing potential).
Key Inclusion Criteria (Parts A, B, and D)
- Age of 18-65 years.
- Body mass index of 18 to 32 kg/m², weight capped at 120 kg.
- No clinically significant abnormalities or history of relevant diseases.
Key Inclusion Criteria (Parts C and E only)
- Age of 18-72 years.
- Body mass index ≥16 kg/m², weight capped at 125 kg.
- Must have dermatologist-confirmed chronic atopic dermatitis (≥12 months). Inadequate response to topical treatments or where they are medically inadvisable.
- Moderate to severe atopic dermatitis
- Validated investigator's global assessment for atopic dermatitis (vIGA-ADTM) score ≥3
- Atopic lesions cover ≥10% of body surface area (BSA)
- Average peak pruritus numeric rating scale (PP-NRS) score ≥4 in the 7 days before randomization.
Key Exclusion Criteria
- Significant health issues, such as: diabetes, positive tests for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B surface antigen (HBsAg), immunodeficiencies, autoimmune diseases, or cancer, history of conditions predisposing to infections.
- History of major metabolic, dermatological, liver, kidney, hematological, or other significant disorders.
- Clinically relevant abnormal lab results, including low blood counts, liver issues, or abnormal kidney function.
- Positive drug/alcohol tests or abnormal vital signs at screening or Day -1.
- Abnormal Electrocardiogram (ECG) findings
- History of drug/alcohol abuse in the past 2 years.
- Donated >500mL blood within 2 months of screening.
- History of severe allergic reactions or hypersensitivity.
Key Exclusion Criteria (Parts A, B, and D only)
- History of atopic dermatitis
Key Exclusion Criteria (Parts C and E only)
- Skin diseases other than atopic dermatitis, significant tattoos, or scarring.
- Receipt of immunoglobulin or blood products within 30 days.
- Atopic dermatitis with ocular symptoms or chronic ocular steroid use.
- Chronic pruritus from conditions other than atopic dermatitis.
- Acute/treated infections or chronic skin infections.
- Current use of sedating antihistamines or corticosteroids.
Recruiting US locations
First OC Dermatology
Irvine, CA 92614
OptiSkin Medical
New York, NY 10128
Equity Medical, LLC
The Bronx, NY 10455
Study contacts (from the official record)
- Lisa Li · +1 617-848-6188 · Lisa.Li@bambusatx.com
Similar studies in California
All dermatology studies in California →- RecruitingHealthy volunteersPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Regeneron Pharmaceuticals
- Location
- West Hills, CA + 5 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
Pfizer
- Location
- Anaheim, CA + 4 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersPhase 1
A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
Sitryx Therapeutics Ltd
- Location
- Fremont, CA + 5 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)
Wynn Medical Center
- Location
- Rosemead, CA
- Eligibility basics
- Ages 18–60